In the present study, we compared the in vitro efficacy of EGFR inhibitors (afatinib and allitinib) and conducted a comprehensive analysis of the molecular mechanisms triggered by KRAS mutations in a panel of lung cancer cell lines. This evidence concerns the gene KRAS and lung carcinoma.